

Special Issue

Advances in Locoregional Therapies for Gastrointestinal Cancer Metastases

Message from the Guest Editor

Paradoxically, as systemic therapy for metastatic gastrointestinal adenocarcinomas continues to significantly improve both in relation to safety and efficacy, the need for aggressive locoregional treatment for metastases has also risen. Despite this contradiction, from a basic and translation science perspective, it is vital to address these “escape” metastases, which, for a given patient, would have resisted traditional and novel more targeted systemic therapies. Fortunately, in the last decade, due to advances in interventional radiology, endoscopy, and radiation therapy, many different modality options have come to the forefront that do not involve invasive operations. However, aggressive and extensive surgical interventions are still often needed. Thankfully, with modern healthcare and our much-improved capabilities to rescue patients from major complications, even these more invasive options have evolved to become less morbid with low mortality rates. In this Special Issue, we hope to explore the rapidly evolving topic of locoregional therapies for metastases from gastrointestinal cancers.

Guest Editor

Prof. Dr. Mazin Al-Kasspooles

Peritoneal Surface Malignancy Program, Division of Surgical Oncology,
Department of Surgery, The University of Kansas Health System,
Kansas City, MO 66160, USA

Deadline for manuscript submissions

15 May 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/249685

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)